European Committee on Antimicrobial Susceptibility Testing

Recommendations

Info

Moraxella catarrhalis EUCAST Clinical Breakpoint Tables v. 7.0, valid from 2017-01-01 Disk diffusion (EUCAST standardised disk diffusion method) Medium: Mueller-Hinton agar + 5% defibrinated horse blood and 20 mg/L β-NAD (MH-F) Inoculum: McFarland 0.5 Incubation: 5% CO 2 , 35±1ºC, 18±2h Reading: Read zone edges as the point showing no growth viewed from the front of the plate with the lid removed and with reflected light. Quality control: Haemophilus influenzae ATCC 49766. For control of the inhibitor component of beta-lactam inhibitor-combination disks, use Staphylococcus aureus ATCC 29213. Penicillins MIC breakpoint (mg/L) Disk content Zone diameter breakpoint (µg) (mm) S ≤ R > S ≥ R < Benzylpenicillin - - - - Ampicillin - 1 - 1 - - Ampicillin-sulbactam 1 2,3 1 2,3 Note A Note A Amoxicillin - 1 - 1 - - Amoxicillin-clavulanic acid 1 4 1 4 2-1 19 19 Piperacillin - 1 - 1 - - Piperacillin-tazobactam Note 3 Note 3 Note A Note A Ticarcillin IE IE IE IE Ticarcillin-clavulanic acid IE IE IE IE Temocillin IE IE IE IE Notes Numbered notes relate to general comments and/or MIC breakpoints. Lettered notes relate to the disk diffusion method. 1. Most M. catarrhalis produce beta-lactamase, although beta-lactamase production is slow and may give weak results with in vitro tests. Beta-lactamase producers should be reported resistant to penicillins and aminopenicillins without inhibitors. 2. For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. 3/A. Susceptibility can be inferred from amoxicillin-clavulanic acid. 4. For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. Phenoxymethylpenicillin - - - - Oxacillin - - - - Cloxacillin - - - - Dicloxacillin - - - - Flucloxacillin - - - - Mecillinam (uncomplicated UTI only) - - - - 51
Moraxella catarrhalis EUCAST Clinical Breakpoint Tables v. 7.0, valid from 2017-01-01 Cephalosporins MIC breakpoint (mg/L) Disk content Zone diameter breakpoint (µg) (mm) S ≤ R > S ≥ R < Cefaclor - - - - Cefadroxil - - - - Cefalexin - - - - Cefazolin - - - - Cefepime 4 4 30 20 20 Cefixime 0.5 1 5 21 18 Cefotaxime 1 2 5 20 17 Cefoxitin NA NA NA NA Cefpodoxime IP IP 10 IP IP Ceftaroline IE IE IE IE Ceftazidime - - - - Ceftazidime-avibactam - - - - Ceftibuten IE IE IE IE Ceftobiprole IE IE IE IE Ceftolozane-tazobactam IE IE IE IE Ceftriaxone 1 2 30 24 21 Cefuroxime iv 4 8 30 21 18 Cefuroxime oral 0.125 4 30 50 21 Notes Numbered notes relate to general comments and/or MIC breakpoints. Lettered notes relate to the disk diffusion method. Carbapenems MIC breakpoint (mg/L) Disk content Zone diameter breakpoint (µg) (mm) S ≤ R > S ≥ R < Doripenem 1 1 1 10 30 30 Ertapenem 1 0.5 0.5 10 29 29 Imipenem 1 2 2 10 29 29 Meropenem 1 2 2 10 33 33 Notes Numbered notes relate to general comments and/or MIC breakpoints. Lettered notes relate to the disk diffusion method. 1. Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. Monobactams MIC breakpoint (mg/L) Disk content Zone diameter breakpoint (µg) (mm) S ≤ R > S ≥ R < Aztreonam IE IE IE IE Notes Numbered notes relate to general comments and/or MIC breakpoints. Lettered notes relate to the disk diffusion method. 52
Page 1 and 2: European C
Page 3 and 4: Guidance on reading EUCAST Breakpoi
Page 5 and 6: Version 7.0, 2017-01-01 Acinetobact
Page 7 and 8: Enterobacteriaceae EUCAST Clinical
Page 13 and 14: Pseudomonas spp. EUCAST Clinical Br
Page 15 and 16: Pseudomonas spp. EUCAST Clinical Br
Page 17 and 18: Acinetobacter spp. EUCAST Clinical
Page 19 and 20: Acinetobacter spp. EUCAST Clinical
Page 21 and 22: Staphylococcus spp. EUCAST Clinical
Page 27 and 28: Enterococcus spp. EUCAST Clinical B
Page 29 and 30: Enterococcus spp. EUCAST Clinical B
Page 31 and 32: Streptococcus groups A, B, C and G
Page 37 and 38: Streptococcus pneumoniae EUCAST Cli
Page 43 and 44: Viridans group streptococci EUCAST
Page 45 and 46: Viridans group streptococci EUCAST
Page 47 and 48: Haemophilus influenzae EUCAST Clini
Page 49 and 50: Haemophilus influenzae EUCAST Clini
Page 51: Haemophilus influenzae EUCAST Clini
Page 55 and 56: Moraxella catarrhalis EUCAST Clinic
Page 57 and 58: Neisseria gonorrhoeae EUCAST Clinic
Page 59 and 60: Neisseria gonorrhoeae EUCAST Clinic
Page 61 and 62: Neisseria meningitidis EUCAST Clini
Page 63 and 64: Neisseria meningitidis EUCAST Clini
Page 65 and 66: Gram-positive anaerobes except Clos
Page 67 and 68: Gram-positive anaerobes except Clos
Page 69 and 70: Clostridium difficile EUCAST Clinic
Page 71 and 72: Gram-negative anaerobes EUCAST Clin
Page 73 and 74: Gram-negative anaerobes EUCAST Clin
Page 75 and 76: Listeria monocytogenes EUCAST Clini
Page 77 and 78: Pasteurella multocida EUCAST Clinic
Page 79 and 80: Corynebacterium spp. EUCAST Clinica
Page 81 and 82: Aerococcus sanguinicola and urinae
Page 83 and 84: Kingella kingae EUCAST Clinical Bre
Page 85 and 86: Mycobacterium tuberculosis EUCAST C
Page 87 and 88: PK/PD (Non-species related) breakpo
Page 89 and 90: PK/PD (Non-species related) breakpo
Page 91 and 92: Dosages EUCAST Clinical Breakpoint
Page 93 and 94: Dosages EUCAST Clinical Breakpoint

European Committee on Antimicrobial Susceptibility Testing

Create successful ePaper yourself

Delete template?

Save as template?